Yazar "Jarrahpour, Aliasghar" seçeneğine göre listele

Listeleniyor 1 - 7 / 7
  • Küçük Resim
    Öğe
    1-(Morpholin-4-yl)-4-(2-nitro-phen-yl)spiro-[azetidine-3,9'-xanthen]-2-one
    (2014) Atioğlu, Zeliha; Akkurt, Mehmet; Jarrahpour, Aliasghar; Heiran, Roghayeh; Özdemir, Namık
    In the title compound, C22H21N3O5, the ?-lactam (azetidin-2-one) ring is nearly planar [maximum deviation = 0.010 (1) Å] and makes dihedral angles of 69.22 (5), 55.32 (5) and 89.42 (4)° with the least-squares planes formed by the four C atoms of the morpholine ring, which adopts a chair conformation, the benzene ring and the xanthene ring system, respectively. In the crystal, C-H?O hydrogen-bond contacts connect neighbouring mol-ecules into infinite zigzag chains running parallel to the b axis.
  • Küçük Resim
    Öğe
    1-[3-(Morpholin-4-yl)prop-yl]-3-[(naph-tha-len-2-yl)oxy]-4-(3-nitro-phen-yl)azeti-din-2-one
    (2014) Atioğlu, Zeliha; Akkurt, Mehmet; Jarrahpour, Aliasghar; Heiran, Roghayeh; Özdemir, Namık
    In the title compound, C26H27N3O5, the ?-lactam (azetidin-2-one) ring is nearly planar [maximum deviation = 0.011?(3)?Å]. The mean plane formed by the four C atoms of the morpholine ring, which adopts a chair conformation, the benzene ring and the naphthalene ring system form dihedral angles of 72.85?(17), 87.46?(15) and 65.96?(11)°, respectively, with the ?-lactam ring. In the crystal, molecules are linked via C—H?O hydrogen bonds, forming inversion dimers with R 2 2(8).
  • Küçük Resim
    Öğe
    3-(2,4-Di-chloro-phen-oxy)-1-(4-meth-oxy-benz-yl)-4-(4-nitro-phen-yl)azetidin-2-one
    (2014) Atioğlu, Zeliha; Akkurt, Mehmet; Jarrahpour, Aliasghar; Heiran, Roghayeh; Özdemir, Namık
    The ?-lactam ring of the title compound, C23H18Cl2N2O5, is nearly planar [maximum deviation = 0.019?(2)?Å for the N atom] and its mean plane makes dihedral angles of 56.86?(15), 68.83?(15) and 83.75?(15)° with the di­chloro-, nitro- and meth­oxy-substituted benzene rings, respectively. In the crystal, mol­ecules are linked by pairs of C—H?O hydrogen bonds, forming inversion dimers with R 2 2(10) loops. The dimers are linked by further C—H?O hydrogen bonds, forming sheets lying parallel to (001). The mol­ecular packing is further stabilized by C—H?? inter­actions.
  • Küçük Resim
    Öğe
    Crystal structure of (E)-1(anthracen-9-ylmethylidene)[2-(morpholin-4-yl)eth-yl]amine
    (2014) Atioğlu, Zeliha; Akkurt, Mehmet; Jarrahpour, Aliasghar; Chermahini, Mehdi Mohammadi; Büyükgüngör, Orhan
    The title compound, C21H22N2O, crystallizes with two independent mol-ecules in the asymmetric unit. In both mol-ecules, the anthracene ring systems are almost planar, with maximum deviations of 0.071 (8) and 0.028 (7) Å, and make dihedral angles of 73.4 (2) and 73.3 (2)° with the least-squares planes formed by the four C atoms of the morpholine rings, which adopt a chair conformation. An intra-molecular C-H?? inter-action occurs. In the crystal, the packing is stabilized by weak C-H?O hydrogen bonds, which connect pairs of molecules into parallel to the c axis, and C-H?? inter-actions.
  • Küçük Resim
    Öğe
    Crystal structure of 4-[(E)-(4-nitro-benzyl-idene)amino]-phenol
    (2015) Atioğlu, Zeliha; Akkurt, Mehmet; Jarrahpour, Aliasghar; Ebrahimi, Edris; Büyükgüngör, Orhan
    The asymmetric unit of the title compound, C13H10N2O3, contains four independent mol-ecules (I, II, III and IV). Mol-ecule IV shows whole-mol-ecule disorder over two sets of adjacent sites in a 0.669 (10):0.331 (10) ratio. The dihedral angles between the aromatic rings are 32.30 (13)° in mol-ecule I, 2.24 (14)° in II, 41.61 (13)° in III, 5.0 (5)° in IV (major component) and 10.2 (3)° in IV (minor component). In the crystal, mol-ecules are linked into layers lying parallel to (024) by C-H?O and O-H?O inter-actions. The layers inter-act by C-H?? and weak aromatic ?-? stacking inter-actions [centroid-centroid distances = 3.8476 (16), 3.725 (3) and 3.733 (5) Å].
  • Küçük Resim
    Öğe
    (E)-4-{[(Morpholin-4-yl)imino]-meth-yl}benzo-nitrile
    (2014) Atioğlu, Zeliha; Akkurt, Mehmet; Jarrahpour, Aliasghar; Heiran, Roghayeh; Özdemir, Namık
    In the title compound, C12H13N3O, the morpholine ring adopts a chair conformation and its mean plane is inclined to that of the benzene ring by 16.78?(12)°. The N—N=C—C bridge, which has an E conformation, has a torsion angle of 173.80?(19)°. In the crystal, mol­ecules stack along the a axis but there are no significant inter­molecular inter­actions present.
  • Küçük Resim
    Öğe
    Investigations of antiproliferative and antioxidant activity of ?-lactam morpholino-1,3,5-triazine hybrids
    (Elsevier, 2020) Ranjbari, Somayeh; Behzadib, Maryam; Sepehri, Saghi; Aseman, Marzieh Dadkhah; Jarrahpour, Aliasghar; Mohkam, Milad; Ghasemi, Younes; Akbarizadeh, Amin Reza; Kianpour, Sedigheh; Atioğlu, Zeliha; Özdemir, Namık; Akkurt, Mehmet; Nabavizadeh,S. Masoud; Turos, Edward
    This article reports for the first time the synthesis of some novel ?-lactam morpholino-1,3,5-triazine hybrids by a [2+2]-cycloaddition reaction of imines 7a–c, 9a–c and 11 with ketenes derived from substituted acetic acids. The reaction was totally diastereoselective, leading exclusively to the formation of cis-?-lactams 8a–l, 10a–f and 12a–c. The synthesized compounds were tested for activity towards SW1116, MCF-7 and HepG2 cancer cell lines and non-cancerous HEK-293 cell line by MTT assay. None of the compounds exert an observable effect on HepG2, MCF-7 and HEK-293 cells, but compounds 7b, 8f, 8g, 8l, 10c, and 10e exhibited excellent growth inhibitory activity (IC50 < 5 ?M) against SW 1116 cells, comparable to that of doxorubicin (IC50 =6.9 ?M). An evaluation of the antioxidant potential of each of the compounds, performed by diphenylpicrylhydrazyl (DPPH) assay, indicated that 7b, 9a, 9b and 9c have strong free radical scavenging activity. UV absorption titration studies reveal that 7b, 8l, 8g and 8f interact strongly with calf-thymus DNA (CT-DNA) in the order of 8l > 7b > 8f > 8g. Collectively, the in vitro capabilities of some of these morpholino-triazine imines and ?- lactams suggest possible applications to development of new antioxidants and DNA binding therapeutics.